Conclusion: Our findings represent the most comprehensive available evidence base to inform patients, families, clinicians, guideline developers, and policymakers on the choice of ADHD medications across age groups. Taking into account both efficacy and safety, evidence from this meta-analysis supports methylphenidate in children and adolescents, and amphetamines in adults, as preferred first-choice medications for the short-term treatment of ADHD. New research should be funded urgently to assess long-term effects of these drugs.
PubMed 30097390 ↗Lisdexamfetamine
Also known as Vyvanse, Elvanse
The short answer. People are split on Lisdexamfetamine — 41% of 281 say it helped. It is most often used for focus: 87% of 200 reports say that improved. It is well studied — 58 meta-analyses on PubMed. The most common complaint is anxiety.
From 439 mentions in total — the rest didn't say how it went and aren't counted.
What Lisdexamfetamine does, according to users
Of the people who reported each effect, the share who said it got better.
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 58 meta-analyses on PubMed ↗ · 112 randomized trials ↗
Conclusion: CBT-ED has the largest efficacy in BN (adults), followed by antidepressants, as well as psychotherapy in BED (mixed). Medications have short-term efficacy in BED (adults).
PubMed 36084848 ↗Conclusion: Cognitive behavioral therapy, lisdexamfetamine, SGAs, and topiramate reduced binge eating and related psychopathology, and lisdexamfetamine and topiramate reduced weight in adults with binge-eating disorder.
PubMed 27367316 ↗Conclusion: Overall, despite a class effect of improving clinical response relative to placebo, there were few differences among the individual ADHD pharmacotherapies, and most studies were at risk of at least one important source of bias. Furthermore, the certainty of the evidence was very low to low for all outcomes, and there was limited reporting of long-term adverse events. As such, the choice between ADHD pharmacotherapies may depend on individual patient considerations, and future studies should assess the long-term effects of individual pharmacotherapies on patient-important outcomes, including qu
PubMed 33085721 ↗126 human trials on ClinicalTrials.gov test Lisdexamfetamine — 94 completed, 5 recruiting now. See all on ClinicalTrials.gov ↗
- Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents · ADHD · 2024
- Vyvanse in Children Aged 6 to 12 Years · Obesity, Childhood · 2026
- Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b) · Loss-of-control Eating, Obesity/Overweight · 2026
What government agencies say
Official records from US, Canadian and EU regulators, each linked to its source.
Lisdexamfetamine is a Schedule II controlled substance in the US. DEA controlled-substance list ↗
Boxed warning (the FDA's strongest label warning): “ABUSE, MISUSE, AND ADDICTION Lisdexamfetamine dimesylate has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including lisdexamfetamine dimesylate, can result in overdose and death, and…”
11 recalls of products named for Lisdexamfetamine. Most recent:
- 2025-11-05 · Class II: Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station… record ↗
- 2025-09-03 · Class II: Labeling: Label Mix-up. A bottle labeled as Lisdexamphetamine Dimesylate Capsules 40mg, contained Lisdexamphetamine Dimesylate Capsules 30mg. record ↗
- 2025-07-23 · Class II: Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 9 month long term stability station… record ↗
Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗
34,600 adverse-event reports mention Lisdexamfetamine. Most often reported:
- Drug ineffective · 4,950
- Fatigue · 2,150
- Off label use · 2,115
- Anxiety · 1,944
- Headache · 1,857
- Nausea · 1,642
Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗
NIH has funded 4 research projects with Lisdexamfetamine in the title, $3,127,139 in total (2009–2023). NIH RePORTER ↗
Plain-language guides from the US government: MedlinePlus: Lisdexamfetamine ↗
Dosage people report
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“It's been a game changer for my focus and energy levels, really brought me back to life.”
“I got diagnosed with ADHD and tried Ritalin and Elvanse and they do help somewhat when I need to learn for an exam but I hate the feeling of being on them.”
“I used vyvanse daily for years. I have not felt pleasure, motivation, or desire in the same way since.”
“Concerta, Vyvanse (they gave me stimulation and a mood booster but it felt really artificial, left me with more depression when I was not taking it)”
Top discussions (5)
- Steroids are so wildly underrated for mental health ↗
- Just an FYI: be extremely careful with prescription amphetamines…. The road off them is long and painful. ↗
- Not everything can be fixed with "diet, sleep, exercise" ↗
- Neuroscience study indicates the narcolepsy drug modafinil enhances cognitive control in healthy people ↗
- don’t go down the rabbit hole, just take adderall ↗
Lisdexamfetamine compared
Other options for focus
Sources
- User reports: 439 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
- FDA drug label (DailyMed) ↗
- FDA adverse-event reports (FAERS) ↗
- FDA recalls ↗
- US DEA ↗
- MedlinePlus (NIH) ↗
- NIH RePORTER ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate